Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while ...
By Michael Erman and Mrinalika Roy Jan 21 (Reuters) - Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of ...
The healthcare company’s forecast for 2026 tops Wall Street’s expectations.
Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...
Zacks Investment Research on MSN
J&J stock down despite Q4 earnings beat, oncology drugs drive sales
Johnson & Johnson’s JNJ fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of ...
As we have previously reported, a group of health insurers and health insurance administrators (collectively, “CareFirst”) filed a class action complaint in 2023 against Johnson & Johnson and Janssen ...
Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...
MedImpact Holdings is planning to offer an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than Stelara. The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals ...
In an extension of a phase 2 clinical drug trial, the treatment Stelara showed long-term favorable results for people with active lupus after taking the medication for two years. Both overall disease ...
JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results